Subject: Potential Multi-drug Resistant Organisms (MDROs) increase during COVID-19 (SARS-CoV-2) Pandemic
Date: 6/12/2020; 15:19:30
Key Points or Updates:
1) With SARS-CoV-2 (COVID-19) currently circulating in New Jersey and the surrounding areas, facilities have reported shortages of personal protective equipment (PPE) and have been operating at contingency and/or crisis capacity to optimize PPE. (https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/index.html)
2) The COVID-19 pandemic may lead to a rise in antimicrobial prescriptions and consequently antimicrobial resistance development and infections. (https://www.cidrap.umn.edu/news-perspective/2020/05/covid-19-presents-antibiotic-stewardship-challenges-opportunities)
3) Facilities may see resurgence of MDROs in healthcare facilities and communities due to both PPE shortages and conservation strategies that were used to preserve PPE in addition to the increased use of antimicrobial agents.
1) Facilities returning to conventional PPE capacity (normal levels of PPE) are reminded to adhere to all infection prevention and control guidance to prevent transmission of MDROs in healthcare settings. This includes the use of all recommended PPE for care of patients with MDROs. (https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html)
2) Resume and continue all current MDRO surveillance activities that may have been suspended or relaxed during the height of the COVID-19 surge in New Jersey.
3) Report all suspect increases in incidence of Carbapenem resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa (CRPA), and Acinetobacter baumannii (CRAB) infections and colonizations. Reminder that all outbreaks or suspect outbreaks of any etiology are immediately reportable to local public health. Contact information for all local health departments (LHDs) in New Jersey is available at: www.localhealth.nj.gov. If LHD personnel are unavailable, healthcare providers should report to the New Jersey Department of Health (NJDOH), Communicable Disease Service at 609-826-5964. If an individual does not live in New Jersey, report the case to NJDOH at the phone number provider within.
4) Continue to report any individual cases of pan-non-susceptible organisms and Candida auris (infections and colonizations).
5) The NJDOH Communicable Disease Services, in partnership with the New Jersey Public Health and Environmental Laboratory (PHEL) and the Centers for Disease Control and Prevention’s Antibiotic Resistance Laboratory Network (CDC ALRN), offers free services to collect, confirm, and characterize CRE, CRPA and CRAB isolates.
This information has been distributed to: DOH Senior Staff; DOH Staff; LINCS Health Officers; LINCS Health Officer Assistants; LINCS Coordinators; LINCS Coordinator Backups; LINCS Epidemiologists; LINCS Health Educators; LINCS Health Planners; LINCS IT Specialists; LINCS Partnership Coordinators; LINCS Public Health Nurses; LINCS Regional Health Planners; LINCS Team Members; LINCS CD Investigators; LINCS REHS; LOCAL Health Officers; LOCAL Public Health; LOCAL CD Investigators; LOCAL Health Educators; LOCAL Public Health Nurses; LOCAL REHS; LOCAL Epidemiologists; Animal Health Organizations; Blood Banks; Community Health Centers (FQHCs); DOH Program Staff; EMS Council; Health Care Organizations; Hospital CEO Assistants; Hospital CEOs; Hospital Emerg Preparedness Coords; Hospital ER Medical Directors; Hospital Infection Control Practitioners; Hospital Medical Directors; Hospital Nursing Directors; Hospital Patient Safety Liaisons; Hospital Quality Liaisons; Hospital Security Directors; Hospital Staff Directory; Hospitals / Veterans; Labs / Non-Sentinel; Labs / Sentinel; Occupational Health Organizations; Public Health Associations; Public Health Council
Further distribution of this message should be directed to: Animal Health Professionals; Community Health Centers (FQHCs); Emergency Medical Services / First Responders; Health Care Facilities / Other; Health Care Providers; Hospital CEOs; Hospital Emerg Preparedness Coords; Hospital ER Medical Directors; Hospital Infection Control Practitioners; Hospital Medical Directors; Hospital Nursing Directors; Hospital Security Directors; Hospitals / Other; Labs / Non-Sentinel; Labs / Sentinel; Pharmaceutical Suppliers; Local Boards of Health; and other partners in your region, as appropriate.
IMPORTANT NOTE: Please do not use reply feature of your email system. If you have questions about the content of this email or any of its attachments, please call your County/City LINCS agency for assistance. LINCS agencies are instructed to contact the individual listed in message above or on the attachment for questions concerning content.